Other
Anifrolumab (blinded)
Anifrolumab (blinded) is an intervention with 2 clinical trials. Currently 2 active trials ongoing.
Total Trials
2
Max Phase
—
Type
COMBINATION PRODUCT
Molecule
—
Success Metrics
Active Trials
2(100%)
Phase Distribution
Ph phase_3
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 32 (100.0%)
Trials by Status
recruiting150%
active_not_recruiting150%
Recent Activity
2 active trials
Showing 2 of 2
recruitingphase_3
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449
active_not_recruitingphase_3
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803
Clinical Trials (2)
Showing 2 of 2 trials
NCT06455449Phase 3
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT05925803Phase 3
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
All 2 trials loaded
Drug Details
- Intervention Type
- COMBINATION PRODUCT
- Total Trials
- 2